Article - Enteromix, Russian cancer vaccine achieves 100% efficacy in clinical trials

Jai Siya Ram http://www.fxlive.in/ Overview & Trial Results 100% efficacy reported in preclinical and early clinical trials Enteromix, an mRNA-based personalized cancer vaccine, has shown 100% effectiveness and safety in early-stage testing, according to reports. The announcement came from official sources during the Eastern Economic Forum. Target cancer types and observed outcomes The vaccine’s primary application appears to be against colorectal cancer, with trials noting significant tumor shrinkage (60–80%) and improved survival rates. Research on vaccines tailored for glioblastoma (an aggressive brain cancer) and various forms of melanoma, including ocular melanoma, is underway. Development & Mechanism mRNA technology meets oncolytic viruses Enteromix employs mRNA vaccine technology—similar to COVID-19 vaccines—but is personalized to match each patient's tumor RNA profile. It reportedly uses a combination of four non-pathogenic viruses engineered both to destroy cancerous cells and activate the patient’s anti-tumor immunity. Collaborating institutions Developed by the Federal Medical and Biological Agency (FMBA) in collaboration with Russia’s National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology (EIMB), the vaccine leverages expertise across virology and oncology research. Clinical Trial Status Phase I human trials underway Russia initiated an open-label, single-center Phase I clinical trial involving approximately 48 volunteers in June 2025. The trials are reported to show very low toxicity, with participants tolerating the vaccine well and displaying complete or significant tumor regression. Prensa Latina Safety and preliminary outcomes Early human trials revealed no serious side effects, robust safety even with repeated doses, and elimination or dramatic reduction of tumors in several patients. Next Steps & Implications Awaiting regulatory approval With promising preclinical and Phase I results, Enteromix now awaits authorization from Russia’s Ministry of Health before wider clinical rollout. Global significance If validated through larger Phase II/III trials, Enteromix could herald a new era of personalized cancer immunotherapy, potentially offering safer and more effective treatment than traditional options like chemotherapy or radiation. Regards FXLive Chandan Singh Rawat MCX Commodity + NSE Equity and Forex Market